RUNX1 and leukemia: The NF-kB inhibitor BMS-345541 inhibits the proliferation of leukemia cells containing RUNX1 mutation, suggesting a potential role of NF-κb inhibitors in targeting RUNX1-related leukemia (Gerritsen et al., 2019).